Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori test for management of dyspepsia: A randomized trial in primary care
Research output: Contribution to journal › Journal article › peer-review
Objectives: An economic evaluation was performed of empirical antisecretory therapy versus test for Helicobacter pylori in the management of dyspepsia patients presenting in primary care.
Methods: A randomized trial in 106 general practices in the County of Funen, Denmark, was designed to include prospective collection of clinical outcome measures and resource utilization data. Dyspepsia patients (n = 722) presenting in general practice with more than 2 weeks of epigastric pain or discomfort were managed according to one of three initial management strategies: (i) empirical antisecretory therapy, (ii) testing for Helicobacter pylori, or (iii) empirical antisecretory therapy, followed by Helicobacter pylori testing if symptoms improved. Cost-effectiveness and incremental cost-effectiveness ratios of the strategies were determined.
Results: The mean proportion of days without dyspeptic symptoms during the 1-year follow-up was 0.59 in the group treated with empirical antisecretory therapy, 0.57 in the H. pylori test-and-eradicate group, and 0.53 in the combination group. After 1 year, 23 percent, 26 percent, and 22 percent, respectively, were symptom-free. Applying the proportion of days without dyspeptic symptoms, the cost-effectiveness for empirical treatment, H. pylori test and the combination were 12,131 Danish kroner (DKK), 9,576 DKK, and 7,301 DKK, respectively. The incremental cost-effectiveness going from the combination strategy to empirical antisecretory treatment or H. pylori test alone was 54,783 DKK and 39,700 DKK per additional proportion of days without dyspeptic symptoms.
Conclusions: Empirical antisecretory therapy confers a small insignificant benefit but costs more than strategies based on test for H. pylori and is probably not a cost-effective strategy for the management of dyspepsia in primary care.
|Journal||International Journal of Technology Assessment in Health Care|
|Number of pages||10|
|Publication status||Published - 2006|
- dyspepsia, Helicobacter pylori, healthcare costs, primary health care, antiulcer agents, PEPTIC-ULCER DISEASE, TEST-AND-TREAT, COST-EFFECTIVENESS ANALYSIS, GASTROESOPHAGEAL-REFLUX DISEASE, TERM ACID SUPPRESSION, 2-YEAR FOLLOW-UP, NONULCER DYSPEPSIA, DUODENAL-ULCER, UNINVESTIGATED DYSPEPSIA, FUNCTIONAL DYSPEPSIA